^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
The NCCN NSCLC Panel recommends afatinib as a first-line therapy option in patients with metastatic nonsquamous NSCLC who have sensitizing EGFR mutations...
Title:
Afatinib (Giotrif) is accepted for use within NHS Scotland
Excerpt:
Afatinib (Giotrif) is accepted for use within NHS Scotland...as monotherapy, for the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
Source:
Title:
The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer
Excerpt:
...- Patients who are diagnosed with locally advanced or metastatic NSCLC with EGFR sensitive mutation positive...
Trial ID:
Source:
Title:
Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma
Excerpt:
...- Patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive advanced Non-Small Cell Lung Cancer (NSCLC)...
Trial ID:
More C2 evidence
Source:
Title:
The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
Excerpt:
...Diagnosed with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFRTKI) naive advanced EGFR mutated non-small cell lung cancer (NSCLC), 3....
Trial ID:
Source:
Title:
The role of Afatinib to come to radical surgery in patients with non-squamous lung cancer with EGFR gene mutation. Il ruolo di Afatinib per giungere alla chirurgia radicale in pazienti con tumore polmonare non squamoso con mutazione del gene EGFR
Excerpt:
...Patients with histologically or cytologically confirmed IIIA or stage IIIB N2 requiring neoadjuvant treatment for pN2 IIIa NSCLCEpidermal Growth Factor Receptor (EGFR) mutation-positive result per the institution's testing methodology. ...
Trial ID:
Source:
Title:
Multicentre, prospective, real-world clinical study of afatinib or gefitinib in combination with first-line chemotherapy for advanced EGFR mutant non-squamous NSCLC
Excerpt:
...1.Non-squamous NSCLC patients confirmed by imaging and histopathology as III B to IV stage; 2.Positive EGFR gene mutation (including 19DEL, 21L858R, G719A, G719C, G719S, L861Q, V689M, N700D, E709K/Q, S720P, L858R, N826S, A839T, K846R, G863D, G719X, S768I complex mutation, G719X complex mutation, etc.); 3.Has not received any previous systemic anti-tumor therapy; 4.No brain metastases, or asymptomatic brain metastases, or symptomatic brain metastases are treated and stable....
Trial ID:
Source:
Title:
A non-interventional, single-arm, prospective clinical study for the efficacy and safety of low-dose alfaatinib combined with pemetrexed and carboplatin in first-line treatment of advanced EGFR mutant non-squamous non-small cell lung cancer
Excerpt:
...7) Gene test from tumor tissues confirmed EGFR sensitive mutation positive (including classical mutation and non-classical mutation :19del, L858R, L861Q, G719X, S768I); 8) No brain metastasis, or accompanied by asymptomatic brain metastasis, or symptomatic brain metastasis after treatment which change to stable; 9) Adequate hematological function: neutrophil absolute count >=1.5x10^9/L, platelet count >= 100x10^9/L exclusion, hemoglobin >= 90 g/L; 10) Adequate liver function: all patients whose total bilirubin level is <= 1.5 times the normal upper limit, and the level of aspartate aminotransferase and aspartate aminotransferase is <=2.5 times the normal upper limit; 11) Adequate renal function: creatinine clearance rate >= 50ml/min (Cockcroft-Gault formula); 12) Adequate coagulation function: international standardized ratio (INR) or prothrombin time (PT) <=1.5 times the normal upper limit. ...
Trial ID:
